Marinus Pharmaceuticals, Inc (MRNS)

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Revolve Group Inc (RVLV), where a total volume of 5,551 contracts has been traded thus far today, a contract volume which is representative of approximately 555,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 77.1% of RVLV's average daily trading volume over the past month, of 719,710 shares..

Every investor in Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) should be aware of the most powerful shareholder...

MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $71.78 per unit.

Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event

Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021

Investors in Marinus Pharmaceuticals Inc (MRNS) saw new options begin trading this week, for the April 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 206 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in 10x Genomics Inc (TXG), where a total volume of 5,314 contracts has been traded thus far today, a contract volume which is representative of approximately 531,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 92.5% of TXG's average daily trading volume over the past month, of 574,295 shares..

Gainers PharmaCyte Biotech (NASDAQ:PMCB) shares rose 119.0% to $7.49 during Wednesday's regular session. Trading ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Marinus Pharmaceuticals Inc(NASDAQ: MRNS) announced topline data from its open-label Phase 2 trial evaluating oral ganaxolone ...

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.41% and -25.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) were unchanged after the company reported Q2 results. Quarterly ...

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its ...

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $75.32 per unit.

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Hilton Worldwide Holdings Inc (HLT), where a total of 19,092 contracts have traded so far, representing approximately 1.9 million underlying shares. That amounts to about 83.5% of HLT's average daily trading volume over the past month of 2.3 million shares..

Marinus Pharmaceuticals Inc(NASDAQ: MRNS)has submitted a marketing applicationto the FDA seeking approval for its ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

Marinus Pharmaceuticals Submits New Drug Application to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder